News >

Intriguing Immunotherapy Regimens Investigated in MCL

Gina Columbus @ginacolumbusonc
Published: Thursday, Apr 27, 2017

Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowski, MD

The treatment paradigm of mantle cell lymphoma (MCL) is in the midst of extensive research with novel immunotherapy combination regimens, explains Grzegorz S. Nowakowski, MD.

State of the Science Summit on Hematologic Malignancies, Nowakowski, an assistant professor of Medicine at Mayo Clinic, spoke to the ever-changing landscape of MCL, the intriguing combinations being studied, and the promise that immunotherapy could hold.

OncLive: You spoke about MCL in your lecture. How has this paradigm evolved?

Nowakowski: MCL is an area where a lot of new agents are being rapidly developed and entering the treatment landscape. What is interesting is that there is this paradigm shift from chemotherapy-based combinations, particularly in the relapsed setting, to more targeted-like approaches. Those include combinations of ibrutinib with rituximab (Rituxan) and lenalidomide with rituximab. Venetoclax (Venclexta) is another active agent in this setting.

The focus of my presentation was to highlight this new data showing activity of those agents in MCL, how they are moving in clinical trials, and how, over time, it can replace the cytotoxic chemotherapy we usually use in this setting. 

Where are some of these regimens currently in the pipeline?

That’s a very good question. Because they started at different times in development, they are at different stages in clinical development and introduction to therapy. The one that is closest to frontline therapy is the combination of lenalidomide and rituximab, or R-squared. This combination has been compared in a randomized study against chemoimmunotherapy. It has been completed and the results are now maturing. It will be a very interesting study to watch. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x